In 608 adults with chronic migraine and medication-overuse headache given brief education, gains with eptinezumab over 12 weeks were sustained to 24 weeks in an open-label extension; placebo switchers improved similarly. TEAEs 30% vs 34%; no new safety signals.
RCTn = 608
Schytz et al. Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results of the randomized RESOLUTION trial